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I
diopathic pulmonary fibrosis (IPF) is a chronic diffuse interstitial lung disease of unknown etiology that is characterized pathologically by inflammation and fibrosis of the lung parenchyma. 1 IPF is progressive and usually fatal. Epidemiologic studies show that cigarette smoking, [2] [3] [4] antidepressant use, 5 gastroesophageal reflux, 6 and occupational dust exposure 2, 3, [7] [8] [9] are potential risk factors for IPF. Patients with IPF are often middle aged, usually between 40 years and 70 years of age. 3, 7 The incidence of the disease increases with age. 7, 10 Aging is an important contributing factor to lifestyle-related diseases, 11 such as obesity, hypertension, diabetes mellitus (DM), hyperlipidemia, and hyperuricemia; therefore, it is possible that lifestyle-related diseases may affect the initiation or progression of IPF.
Among these lifestyle-related diseases, DM is a frequent complication in patients with IPF, but the prevalence is unknown. The aim of this study was to test, using a case-control approach, the following hypotheses: (1) lifestyle-related diseases, including DM, may increase the risk of IPF; and (2) patients with IPF and DM may be different from those without DM.
Materials and Methods

Study Design
A case-control approach was used to investigate associations between IPF and cigarette smoking, obesity, and lifestyleassociated diseases, such as hypertension, DM, hyperlipidemia, and hyperuricemia. Sixty-five patients with IPF were admitted to Nippon Medical School Hospital between 1995 and 2000. The diagnosis of IPF was based on clinical history, clinical examination, and high-resolution CTs (HRCTs) of the chest. Results of video-assisted thoracoscopic lung biopsy, transbronchial lung biopsy, and/or BAL, corresponding to the international consensus statement of IPF of American Thoracic Society and European Respiratory Society, 12 were also used when available, either alone or in combination, to assist diagnosis. Video-assisted thoracoscopic lung biopsy was performed in six cases, transbronchial lung biopsy in 33 cases, and BAL in 41 cases. All patients had progressive dyspnea on exertion, basal fine crackles through auscultation, and predominantly peripheral, subpleural, bibasal fine reticular shadows and/or honeycombing, occasionally with traction bronchiectasis and bronchiolectasis on HRCT. There was no evidence of either coexisting collagen-vascular disease or history of occupational dust exposure in any of the patients.
Control subjects were 184 people with no evidence of lung disease on their chest radiographs. The age-and sex-matched subjects were randomly selected from 15,798 subjects admitted to Omiya City Clinic for routine medical examination between September 1999 and August 2000. The study protocol was approved by our institutional review board for human studies, and all patients and control subjects gave informed consent to the study.
The medical records of patients and control subjects were analyzed retrospectively. Sex, age, body height, body weight, cigarette smoking history, BP, leukocyte count, fasting blood sugar (FBS), glycosylated hemoglobin (HbA Ic ), and plasma level of C-reactive protein (CRP), lactate dehydrogenase (LDH), total cholesterol (T-chol), triglyceride, uric acid (UA), vital capacity (VC), FVC, and FEV 1 were evaluated in both patients and control subjects. In patients with IPF, the diffusion capacity of the lung for carbon monoxide (Dlco), corrected by alveolar volume (Va), and serum level of KL-6 and surfactant protein-D were also evaluated.
The data that were extracted from the medical records and described in the preceding paragraph were then associated with the following clinical diagnostic criteria. Obesity was considered to be present when body mass index (BMI) was Ͼ 25. 13 Hypertension was identified when systolic BP was Ͼ 140 mm Hg and/or diastolic BP was Ͼ 90 mm Hg, 14 and/or patients had a history of treatment with antihypertensive drugs. A diagnosis of DM was associated with the following criteria 15 : FBS Ͼ 126 mg/dL and/or HbA Ic Ͼ 6%. Any therapy, including diet, exercise, and/or medication, also was considered for identifying patients with DM. Hyperlipidemia was associated with T-chol Ͼ 240 mg/dL and/or triglyceride Ͼ 150 mg/d, 16 as well as treatment with any medications for hyperlipidemia. Hyperuricemia was considered present when UA was Ͼ 7.0 mg/dL, 17 and/or subjects had been treated with any medications for hyperuricemia.
Statistical Analysis
Conditional logistic regression analysis was used to assess the role of several variables as risk factors for the development of IPF. Statistically significant differences in demographic factors between patients and control subjects, as well as differences between patients with IPF with and without DM, were evaluated by either 2 or the Mann-Whitney U test. StatView (version 5.0; SAS Institute; Cary, NC) was used for all statistical analyses. Values of p Ͻ 0.05 were considered significant.
Results
A total of 65 cases of IPF were identified, but only 52 patients were eligible for further study since 13 of the group had been treated previously with corticosteroids. Exposure to corticosteroid therapy influences glucose tolerance. All 184 control subjects were appropriate for study. All patients and control subjects were Japanese. We examined the nonadjusted odds ratio (OR) using univariate analysis (Table 2 ). Patients and control subjects differed in their smoking histories and the prevalence of DM. Percentages of ever-smokers were 84.6% for patients and 50.5% for control subjects. The prevalence of DM was 32.7% for patients and 11.4% for control subjects. The prevalences of obesity (19.2% vs 17.4%), hypertension (24.4% vs 13.0%), hyperlipidemia (19.2% vs 46.0%), and hyperuricemia (5.9% vs 12.0%) were similar between patients and control subjects, respectively.
A history of ever-smoking was associated with significantly increased prevalence for IPF (OR, 5.30; 95% confidence interval [CI], 2.34 to 11.80). DM was also associated with an increased prevalence for IPF (OR, 3.88; 95% CI, 1.85 to 8.12). To avoid the possibility of confounding of every factor, we examined the adjusted OR for all factors by multivariate analysis ( Table 2 ). The adjusted OR of smoking was 5.40 (95% CI, 2.30 to 12.66), and the adjusted OR for DM was 4.06 (95% CI, 1.80 to 9.15). We evaluated the difference between patients with IPF and DM and patients with IPF without DM (Table  3) . Only FBS (145.6 g/dL vs 92.0 g/dL) and HbA Ic (6.26% vs 5.32%), respectively, were different between the two groups.
Discussion
Our results support the hypothesis that DM increases the risk of IPF. In the international consensus statement on IPF from American Thoracic Society and European Respiratory Society, 12 there is no information about the association of IPF and DM. Our report documents such a relationship. The prevalence of DM was 32.7% for patients with IPF and 11.4% for control subjects. The OR of DM for IPF by multivariate analysis was 4.06 (95% CI, 1.80 to 9.15). It has been reported that the prevalence of DM for Japanese individuals Ͼ 40 years old was 10.0%. 18 Since our study was a small-scale, case-control study, the statistical power available would be limited. In such a case-control study, it is important to remove the biases. In our study, the diagnostic criteria of IPF were strict and represent a high level of specificity. We also excluded all patients with a history of treatment with corticosteroids, because exposure to corticosteroid therapy influences glucose tolerance. We selected control subjects from those who had been admitted for routine medical examination; however, residents of Japan are on the same health insurance list. In addition, approximately 67 million people undergo a routine annual medical examination. The routine medical examination is very popular in Japan. Our patient and control populations are likely to be comparable for several reasons. First, Japan is not an ethnically diverse country. In addition, all residents of Japan are registered in the same health-care system. The annual medical examination that is allowed by the system is utilized by the majority of the subscribers, creating a database from which a random sample of healthy control subjects can be generated. The access to this database enabled us to use medical records to obtain retrospective clinical data that could be related to lifestyle-associated diseases. Such an approach eliminated any observer bias. The patients with clinical disease originated from the same general population as the healthy control subjects, even though the study locations were physically different. A limiting factor in our study, based on retrospective analysis of clinical records, was the inability to compare socioeconomic status between patients and control subjects. The impact of socioeconomic status on lifestyle-related diseases is an important variable that must be investigated in future studies. Although patients with chronic respiratory disease such as COPD and patients with other types of interstitial lung diseases would be good control groups, we could not investigate them. We chose to focus on IPF with the worst prognosis. This is the first evaluation of DM on pulmonary fibrosis, but we hope to evaluate other types of pulmonary fibrosis in future studies. Suarez and coworkers 19 reported that the prevalence of DM in male patients with interstitial lung diseases, not only IPF but also nonspecific interstitial pneumonia and hypersensitivity pneumonitis, was higher than that in patients with lung cancer and in the general population. The prevalence of DM in patients with "pulmonary fibrosis" has been reported previously. Abramowitz and coworkers 20 found that in the 2,832 patients with pulmonary fibrosis, 255 patients (9%) also had DM; however, the data in this report were compromised because only the discharge diagnosis from medical records was used to characterize patients. In addition, the diagnosis of pulmonary fibrosis was probably performed without HRCT. Suga and coworkers 21 reported that 18 patients (24.0%) with idiopathic interstitial pneumonias had DM, as compared to 9 patients (4.5%) in the disease control group; however, the control group in the previously cited study included pulmonary diseases, such as lung cancer, sarcoidosis, pneumonia, tuberculosis, emphysema, and pneumothorax. In addition, the case selection was based on a diagnosis of idiopathic interstitial pneumonias, and it is likely that many types of interstitial pneumonia were included. Patients were not compared with healthy control subjects. Furthermore, the patients with lung cancer and pneumonia were likely to be nutritionally unstable. To eliminate some of these variables related to pulmonary diseases other than IPF, we selected the control group from subjects without evident pulmonary diseases.
Patients with IPF were similar clinically with the exception of the diagnosis of DM; therefore, DM is likely to be an independent risk factor for IPF. The results of FBS and HbA Ic testing indicated that the patients with IPF and DM did not have severe DM disease.
Our results support previous studies 2-4 reporting increased risks for IPF in association with cigarette smoking. Percentages of ever-smokers were 84.6% for patients with IPF and 50.5% for control subjects. The adjusted OR of cigarette smoking was 5.40 (95% CI, 2.30 to 12.66). In previous studies, smoking status was divided into never-smoking, former smoking, and current smoking. Most patients with IPF have a history of cough and exertional dyspnea and have stopped smoking prior to, or at the time of, diagnosis. Because our data analysis showed no differences between former and current smokers in patients with IPF, we have used only never-smoking and ever-smoking as a means of grouping patients.
Leukocyte counts, CRP levels, and LDH levels in plasma were higher in patients with IPF than in control subjects, as has been previously reported. 22, 23 Whether these alterations are profiles of IPF remains to be determined.
It is unclear why DM increases the risk of IPF. We reported that hyperglycemia might influence the severity of bleomycin-induced lung fibrosis in mice. 24 Matsuse and coworkers 25 found that advanced glycation end products-modified proteins accumulated both in lung samples from patients with diffuse alveolar damage as well as in lung samples from patients with IPF. In the Maillard reaction, prolonged incubation of proteins with glucose leads to advanced glycation end products. 26 Further study will be needed for clarification of the role of DM in a high number of patients with IPF.
Conclusion
Our study has shown that DM is prevalent in patients with IPF. DM may be a risk factor for IPF.
